|
US6136597A
(en)
|
1997-09-18 |
2000-10-24 |
The Salk Institute For Biological Studies |
RNA export element
|
|
US7419829B2
(en)
|
2000-10-06 |
2008-09-02 |
Oxford Biomedica (Uk) Limited |
Vector system
|
|
US7575924B2
(en)
|
2000-11-13 |
2009-08-18 |
Research Development Foundation |
Methods and compositions relating to improved lentiviral vectors and their applications
|
|
RU2305708C2
(ru)
|
2001-10-02 |
2007-09-10 |
Энститю Клейтон Де Ля Решерш |
Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
|
|
DK1737966T3
(da)
|
2004-04-02 |
2012-07-09 |
Univ Texas |
Cancerspecifik promotorer
|
|
US8865881B2
(en)
|
2011-02-22 |
2014-10-21 |
California Institute Of Technology |
Delivery of proteins using adeno-associated virus (AAV) vectors
|
|
GB201206455D0
(en)
|
2012-04-12 |
2012-05-30 |
Royal Holloway & Bedford New College |
Gene expression
|
|
AU2014240045A1
(en)
|
2013-03-15 |
2015-09-10 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
|
CA2906770A1
(en)
|
2013-03-15 |
2014-09-18 |
Vlp Biotech, Inc. |
Palivizumab epitope-based virus-like particles
|
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
CL2014003590A1
(es)
|
2014-12-30 |
2015-07-10 |
Univ Chile |
Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
GB2547179A
(en)
|
2015-10-26 |
2017-08-16 |
Quethera Ltd |
Genetic construct
|
|
EP3368672B1
(en)
|
2015-10-27 |
2020-11-25 |
Celltheon Corporation |
Chimeric post-transcriptional regulatory element
|
|
US20190161530A1
(en)
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
MX2018014256A
(es)
|
2016-05-20 |
2019-08-16 |
Harvard College |
Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
|
|
CA3053534A1
(en)
|
2017-02-17 |
2018-08-23 |
Purdue Research Foundation |
Targeted ligand-payload based drug delivery for cell therapy
|
|
WO2020219868A1
(en)
*
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2021081280A1
(en)
*
|
2019-10-23 |
2021-04-29 |
Shire Human Genetic Therapies, Inc. |
Adeno-associated virus vectors based gene therapy for hereditary angioedema
|
|
US20230390418A1
(en)
*
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|